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Conclusions: According to ICRU 83 report, to correctly evaluate PTV 
volumes extended outside the body surface, several methods have 
been proposed, for example by extending the beam intensity values 
from the breast periphery to the regions outside the body. By 
attributing a density value to PTV-SV2 we were able to achieve this 
same goal even without the use of any inverse IMRT tools. 
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Purpose/Objective: Different techniques of accelerated partial breast 
irradiation have been described in the literature. Using a volumetric 
modulated arctherapy technique (VMAT) allow a better target 
coverage and better protection of critical organs compare to three-
dimensional conformal radiotherapy (RC3D). We present here the 
dosimetric results of the first patients treated with CRLC Val d'Aurelle 
in Montpellier for an accelerated treatment (IPAS). 
Materials and Methods: Between may 2011 and July 2012, ten 
patients were treated by IPAS for breast cancer using a VMAT 
technique. Dose was 40 Gy, 4 Gy per fraction twice fractions per day 
separate from 6 hours, spread over a week. PTV was generated by 
expansion of the lumpectomy cavity of 1.8 cm. Treatment was 
delivered by two arcs of 270 degrees using the technology RapidArc 
(Varian 21 EX) with a collimator rotation of 45 degrees. The 
optimization and dose calculation were performed with version 
10.0.28 of the planning system and Eclipse AAA algorithm with a 2.5 
mm calculation grid. The constraints were for the PTV D99% ≥ 95%, D95% 
≥ 100% of the prescribed dose. For the ipsilateral lung: V20Gy <3% V10Gy 
<10% V5Gy <20% and V20Gy <1% V10Gy <2% V10Gy <3% for the contralateral 
one. Concerning the eart for V20Gy <1% V5Gy <70%. 
Results: The average volume of the PTV was 99.9 cc [39.8 to 219.5] 
(mean and range). An average of 95% of the PTV received 99.7% of the 
prescribed dose [99.4 to 99.9]. Hotspots: V110Gy represented 0.34% [0 
to 1.42] PTV. The homogeneity index defined as: HI = (D2% - D98%) / D median 
was 0.056 [0.040 to 0.085]. The dose to healthy tissues (OAR) was 
optimal. For the ipsilateral lung V20Gy was 0.27% [0 to 2.67], the V10Gy 
1.60% [0 to 10.47], 6.17% V5Gy [0 to 19.94] . Regarding the 
contralateral lung V20Gy and V10Gy are equal to 0% and V5Gy to 0.28% [0 
to 2.78]. For the heart V5Gy was 3.10% [0 to 23.59], all other 
constraints were largely reached. The average number of monitor unit 
was issued 580UM [473-655] and the processing time was 3.2 minutes 
for two arcs. 
Conclusions: IPAS by RapidArc provides excellent coverage of the PTV 
while preserving healthy tissue. Processing speed improves its quality 
because intrafractions movements are reduced. We have not observed 
severe acute toxicities. 
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Purpose/Objective: To evaluate compliance of patients with 
carcinoma breast to cancer directed therapy in multidisciplinary 
cancer care setting. 
Materials and Methods: The study included a total of 117 patients. 
Patients were assessed as per patient, disease & treatment related 
factors. Surgery included modified radical mastectomy or breast 
conservation surgery. Chemotherapy comprised of 6 cycles of FEC 
based or 4 FEC/4Docetaxel in neoadjuvant & adjuvant setting 
respectively. Herceptin therapy was offered to patients with 
HER/neu2 overexpression. Radiation therapy delivered was 50 
Gy/25#/5 wks, a boost of 16Gy/8#/1.5 wks was delivered to the 
lumpectomy cavity for patients undergoing BCS. All patients were 
considered for tamoxifen/aromatase inhibitors depending upon 
receptor & menopausal status. For the purpose of study compliance 
was defined as all patients who were able to complete the stipulated 
treatment (excluding the hormone therapy) as intended at the 
primary multidisciplinary clinic The key factors evaluated for 
compliance and overall treatment time were date of initiation of 
cancer directed therapy, surgery date, chemotherapy initiation & 
completion dates, radiation start & completion date. Overall 
treatment time was calculated from the day of initiation of cancer 
directed therapy to completion of therapy (before the initiation of 
hormone therapy). 
Results: Seventy percent of the patients presented in loco-regionally 
advanced disease. Most of the patients (66%) were between 40-69 
years of age group. Receptor status positivity for Estrogen and 
progesterone receptor were 43% & 36 % respectively whereas Her-
2/neu was over-expressed in 36% of the patients. Eighty nine percent 
of the patients were subjected to curative therapy whereas 11% of the 
patients were subjected to palliative treatment. Modified radical 
mastectomy was performed in 72% of the patients whereas only 14% of 
the patients underwent breast conservation therapy. Neoadjuvant 
chemotherapy was administered in 51%of the patients while 34% of 
the patients received adjuvant chemotherapy. Sixty eight per cent of 
the patients received 50Gy/25#/5 wks whereas 14% received further 
lumpectomy boost. Eighty six per cent of the patients were compliant 
to cancer directed therapy. The overall median treatment time was 
262 (92-335) days.  
Conclusions: Eight six per cent of the patients were compliant to 
cancer directed therapy whereas fourteen per cent of the patients 
failed to comply to the stipulated treatment before the initiation of 
hormonal therapy. For compliant patients the median overall 
treatment time was 262 days. 
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Purpose/Objective: Although electronic health records are currently 
more common place, not all the information can be used in automatic 
processes, mainly due to the use of free text structured to abstract 
certain values in a table related to the health records. The objective 
of this study is to test a simple natural language processor (NLP) for 
automatic identification of tumor size from the pathology report (PR) 
before adjuvant radiotherapy for breast cancer (BC). 
Materials and Methods: Consecutive PRs were identified by searching 
a database of BC patients treated with surgery and adjuvant radiation 
therapy between January - April 2012. The inclusion criteria included: 
(1) patients having an unstructured free-text PR; (2) non-metastatic 
BC; (3) non simultaneous contralateral BC. Our approach starts with 
the detection and extraction of the tumor's size characteristics in 
unstructured free text from an electronic health record source (PR) 
using a simple NLP. Secondly, based on the data extracted, we 
applied different classification trees from the java data-mining open 
source software: weka. Three data mining algorithms were used: J48 
based on C4.5 algorithm, LADtree, and NaiveBayes. A classification 
algorithm not based on data-mining was also applied. The PRs were 
reviewed and annotated by a 3rd year radiation oncology resident 
according to the 7th edition TNM staging system. Finally, an expert 
senior radiation oncologist revised the divergent classification results 
found between the resident and the different algorithms. 
Results: A total of 68 PRs (test set) met the inclusion criteria. The 
pathological tumor size classification is shown (Table). The median PR 
length was 88 words (range, 69–244). Compared to human 
classification (resident), the coincidence rates with the non-data 
mining based algorithm and the J48, LADtree, and NaiveBayes 
algorithms were 86%, 83%, 82%, and 77%, respectively. After the 
expert revision, the coincidence rates between algorithms and human 
classification were: 96%, 93%, 87%, and 82%, respectively. There were 
only 3 errors when using the non-based on data mining algorithm, 
being 5, 9 and 12 when using J48, LADtree, and NaiveBayes 
algorithms, respectively. The errors in the classification by the 
algorithms were mainly due to lack of recognition of multifocal status 
and inflammatory disease. The resident´s classification errors mostly 
resulted from use of the clinical T stage when the PR revealed a 
complete response after neoadyuvant chemotherapy. 
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  Number of patients (%) 
T stage 
pTis 
pT0 
pT1a 
pT1b
pT1c 
pT2 
pT3 
pT4b
pT4d
4 (6) 
2 (3) 
3 (4) 
24 (36) 
20 (29) 
3 (4) 
1 (1) 
2 (3) 
9 (12) 
 
Conclusions: This system based on artificial intelligence automatically 
enables the classification of tumor size in BC. Among the data mining 
algorithms, the J48 algorithm had the highest percentage of correctly 
classified cases and allows changes (i.e.: guideline updates). This tool 
would save time in the data collection, prevent errors, and improve 
tumor classification as well as the quality of the therapeutic decision.  
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Purpose/Objective: Breast conserving surgery and post-operative 
whole breast radiotherapy (RT) have proved to reduce local 
recurrence and improve survival of early stage breast cancer patients. 
On the other hand, it has been demonstrated that long-term survivors 
have a significantly higher risk of lung complications and cardiac 
death as a consequence of heart and lung irradiation during tangential 
breast RT. Respiratory gating RT provides a chance to reduce heart 
and lung doses. This study evaluates the cardiopulmonary dose sparing 
of a prospective-gating RT for left breast cancer using a four-
dimensional computed tomography (4DCT) technique.  
Materials and Methods: Patients with early left breast cancer, 
referred for adjuvant radiotherapy to our Institution,were enrolled in 
this study. For each patient, two simulation CT-scans were acquired: 
the first during free breathing and the second on prospective gating 
during deep inspiration breath-hold. The scans were monitored by the 
Varian RPMTM respiratory gating system. Whole heart and pericardium 
was contoured starting superiorly just below the left pulmonary 
artery. For each patient, two treatment plans, based on the two CT 
studies, were performed with conformal tangential fields. Maximum 
lung distance (MLD) was measured on beams eye view. Mean heart 
dose (MHD), heart V25, ipsilateral lung V20 and V30 were evaluated. 
Dose-volume histograms were calculated and compared by the paired 
sample T-test. 
Results:  
 From January to November 2012, 71 patients were enrolled. Median 
age was 50 years (range 30-76),the mean breathing period was 4.3s 
(range 2-12.9), and the mean 4DCT scanning time was 12.2 s (range 5-
19). Overall patients’ compliance was good The average MHD was 3.2 
Gy (range 0.90-8.70) in the 4D plans and 1.8 Gy (range 0.50-4.70) in 
the 3D plans (p<0.0001). The mean heart V25 was 2.25% (range 0-
12.60) and 0.14% (range 0-3.40) for 3D and 4D plans, respectively 
(p<0.0001). The average MLD was 2.17 cm (range 0.97-3.74) on 3D 
plans and 2.43 cm (range 1.25-4.0) on the 4D plans (p<0.0001). The 
mean lung V20 and V30 were 11.28% (range 1.70-27.50) and 9.37% 
(range 1.10-24.80) for 3D plans, and 9.25 % (range3.50-20.60) and 
7.89% (range 2.40-30) for 4D plans (p<0.0001 and p=0.0035, 
respectively).  
Conclusions: Prospective gating tangential RT to left breast allows the 
delivery of a significantly lower dose to heart. The MLD was 
significantly higher on 4D plans, but the ipsilateral lung received an 
overall smaller dose of RT, as demonstrated by the significantly lower 
V20 and V30.  
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Purpose/Objective: The aim of this prospective study is to evaluate 
feasibility, early and late skin toxicity in women treated with 
hypofractionated whole breast irradiation schedule for breast cancer. 
Materials and Methods: Between 2/ 2008 and 4/ 2011, 40 women 
with invasive early breast cancer were treated with conservative 
surgery followed by sentinel-node biopsy in 47.5% and axillary 
dissection in 40%. No axillary node surgery was performed in 12.5% of 
cases. The median age was 72 years (range 56-85). Hystology was as 
follows: infiltrating ductal carcinoma 30/40 pts , infiltrating lobular 
carcinoma 6/40 pts, CDI and CLI 1/40 pt, others 3/40 pts. Stage was 
as follows: pT1 in 33 pts (82.5%), pT2 in 7 pts (17.5%). The axillary 
lymph nodes were negative in 77.5% and positive (pN1a) in 12.5% . 
Thirty-five pts received adjuvant hormone therapy and 3 pts received 
adjuvant systemic therapy respectively. Radiation therapy was 
delivered by means of two opposed tangential fields. Using the 
original planning computer tomography scans the entire breast and 
OARs were delineated. The DVH histograms were accepted just if PTV 
was included in ICRU constraints. All pts were treated with 6-15 MV x-
rays. Median whole-breast irradiation dose prescribed was 40.05Gy 
(range: 40 - 42.5 Gy) administered in 15-16 fractions of 2.5-2.67Gy (5 
fractions/week). Boost irradiation to the tumor bed with the doses of 
2 to 3 Gy/fraction was performed in 4 cases. No attempt was made to 
treat the axilla or the supraclavicular or internal mammary nodes. 
Results: All pts completed the schedule. The median follow-up was 18 
months (range 16-54 months). All pts were routinely evaluated to 
register acute side effects and late skin toxicity according to RTOG 
criteria. At the end of treatment 50% presented grade 0 acute skin 
toxicity, 35% had grade 1 and 15% had grade 2. At 6 months there 
were 30% cases of grade 1 skin toxicity and 7.5% of grade 2. At 12 
months 45% and 5 % of pts presented with clinical grade 1 and grade 2 
fibrosis respectively and 5% presented hyperpigmentation. At 24 
months, with 21 patients evaluated, just 1 pt showed grade 2 late 
fibrosis. The remaining pts were free of side effects. No pts 
experienced local relapse, nor distant metastasis. 
Conclusions: Our data showed a good feasibility of the 
hypofractionated schedule in terms of acute and late skin toxicity. 
The hypofractionated schedule shortens the overall treatment time 
and represents a biologically acceptable alternative to the traditional 
6 weeks regime. 
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Purpose/Objective: Functional imaging is known as accurate tool for 
evaluation of chemotherapy (CHT) efficacy in patients (pts) with 
breast cancer (BC). We determine the group of patients with excellent 
functional response to neoadjuvant chemotherapy as a potential 
candidates for breast irradiation instead of mastectomy. 
Materials and Methods: 50 primary pts with advanced BC (T3-4, N1-2) 
were included in this study. Breast scintigraphy (BS) was done before 
the start of CHT and after 2-6 cycles of treatment with taxane-
doxorubicin based regimes ± trastuzumab. BS was performed 10-15 
min after i/v injection of 740 MBq of 99mTc-MIBI. Qualitative and 
semiquantitative scores were used to qualify dynamic of tracer uptake 
